Myriad Genetics (Salt Lake City) announced on May 6 that it will expand its direct-to-consumer (DTC) marketing campaign for BRACAnalysis, its flagship genetic test for hereditary breast and ovarian cancer. The first campaign debuted last September in the northeastern United States at an estimated cost to Myriad of $8 million and concluded in March of 2008. A second campaign of approximately the same size and cost will be held in the southern region of the country, primarily Texas and Florida, which Myriad says represents 18 percent of the U.S. market for BRACAnalysis, compared with 12 percent for the northeast region.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

June 2008 - Table of Contents

DTTR June 2008 (full PDF issue)

SACGHS Report Calls for Expanded FDA Oversight

Myriad Genetics to Expand Direct-to-Consumer Marketing Efforts

FDA Clears Third Warfarin Genotyping Test

Congress Passes Ban on Genetic Discrimination, Measure Ready for Signing

Genzyme Genetics Launches Testing for Spinal Muscular Atrophy

Inverness Completes Acquisition of Matria Healthcare

SACGHS Calls for Expanded Regulation, Resources for Genetic Testing

Part B Lab Spending Climbs to $6.8 Billion in 2007

LabCorp Expands Companion Diagnostic Development Focus

Beckman Coulter Licenses HCV Test from Siemens

Group B Strep Increases Among Adults

NEJM Study Finds Genetic Links to Neuroblastoma

Saliva-Based Method Shows Promise for Early Diagnosis of Heart Attack

Enzo Biochem Buys Biomol to Boost Life Sciences Business

IVD Stocks Lose 4%; Affymetrix Drops 34%

Outreach Testing by the Numbers